Literature DB >> 28338552

Is the Future of Coronary Arterial Revascularization a Hybrid Approach?: The Canadian Experience Across Three Centers.

Vincenzo Giambruno1, Ahmad Hafiz, Stephanie A Fox, Hugues Jeanmart, Richard C Cook, Feras H Khaliel, Patrick Teefy, Kumar Sridhar, Shahar Lavi, Rodrigo Bagur, Varinder K Randhawa, Ivan Iglesias, Philip M Jones, Christopher C Harle, Daniel Bainbridge, Michael W A Chu, Bob B Kiaii.   

Abstract

OBJECTIVE: Hybrid coronary revascularization offers and combines the advantages of both surgical and percutaneous revascularization and eliminates at the same time the disadvantages of both procedures. The objective of this study was to assess graft and stent patency at 6 months, rate of bleeding, intensive care unit and hospital stay, rate of reintervention, and long-term clinical follow-up.
METHODS: From March 2004 to November 2015, a total of 203 patients underwent robotic-assisted minimally invasive direct coronary artery bypass graft of the left internal thoracic artery to the left anterior descending artery and PCI of a non-left anterior descending vessel in a single or two stage, at three different centers. Patients underwent 6-month angiographic follow-up. The mean ± SD clinical follow-up was 77.82 ± 41.4 months.
RESULTS: Successful hybrid coronary revascularization occurred in 196 of the 203 patients. One hundred forty-six patients underwent simultaneous surgical and percutaneous intervention. Nineteen patients underwent PCI before surgery, and 38 patient underwent PCI after surgery. No in-hospital mortality occurred. The mean ± SD ICU stay was 1 ± 1 days and the mean ± SD hospital stay was 5 ± 2 days. Only 13.3% of the patients required a blood transfusion. Six-month angiographic follow-up has been performed in the 95 patients, and it demonstrated a left internal thoracic artery anastomotic patency of 97.9% and stent patency of 92.6%. A total of 77.8 ± 41.4-month clinical follow-up demonstrated 95.1% survival, 92.6% freedom from angina, and 90.7% freedom from any form of coronary revascularization.
CONCLUSIONS: Hybrid coronary revascularization seems to be a promising and safe revascularization strategy. It provides selected patients with an alternative, functionally complete revascularization with minimal surgical trauma and good long-term clinical outcomes.

Entities:  

Mesh:

Year:  2017        PMID: 28338552     DOI: 10.1097/IMI.0000000000000355

Source DB:  PubMed          Journal:  Innovations (Phila)        ISSN: 1556-9845


  4 in total

1.  Postoperative complications after elective coronary artery bypass grafting surgery in patients with sleep-disordered breathing.

Authors:  Maria Tafelmeier; Teresa Weizenegger; Sarah Ripfel; Miriam Fauser; Bernhard Floerchinger; Daniele Camboni; York Zausig; Sigrid Wittmann; Marzena A Drzymalski; Florian Zeman; Christof Schmid; Lars S Maier; Stefan Wagner; Michael Arzt
Journal:  Clin Res Cardiol       Date:  2018-06-12       Impact factor: 5.460

2.  Hybrid coronary revascularization vs. percutaneous coronary interventions for multivessel coronary artery disease.

Authors:  Edward L Hannan; Yi-Feng Wu; Kimberly Cozzens; Jacqueline Tamis-Holland; Frederick S K Ling; Alice K Jacobs; Ferdinand J Venditti; Peter B Berger; Gary Walford; Spencer B King Iii
Journal:  J Geriatr Cardiol       Date:  2021-03-28       Impact factor: 3.327

3.  Clinical outcomes of a combined transcatheter and minimally invasive atrial septal defect repair program using a 'Heart Team' approach.

Authors:  Shahrukh N Bakar; Daniel J P Burns; Pantelis Diamantouros; Kumar Sridhar; Bob Kiaii; Michael W A Chu
Journal:  J Cardiothorac Surg       Date:  2018-01-18       Impact factor: 1.637

4.  Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year-Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS).

Authors:  Vladimir Ganyukov; Nikita Kochergin; Aleksandr Shilov; Roman Tarasov; Jan Skupien; Wojciech Szot; Aleksandr Kokov; Vadim Popov; Kirill Kozyrin; Olga Barbarash; Leonid Barbarash; Piotr Musialek
Journal:  J Interv Cardiol       Date:  2020-01-03       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.